Vitalhub Corp. (TSE:VHI - Free Report) - Investment analysts at Cormark decreased their FY2025 earnings per share estimates for shares of Vitalhub in a report issued on Wednesday, March 5th. Cormark analyst G. Fairweather now forecasts that the company will post earnings per share of $0.20 for the year, down from their previous estimate of $0.21. The consensus estimate for Vitalhub's current full-year earnings is $0.23 per share. Cormark also issued estimates for Vitalhub's FY2026 earnings at $0.31 EPS.
A number of other brokerages also recently weighed in on VHI. Scotiabank set a C$14.00 target price on Vitalhub and gave the stock an "outperform" rating in a research note on Thursday, January 30th. TD Securities raised Vitalhub to a "strong-buy" rating in a research report on Monday, November 25th. Finally, Canaccord Genuity Group raised their target price on Vitalhub from C$12.00 to C$12.50 and gave the company a "buy" rating in a research report on Thursday, January 16th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of C$11.60.
Check Out Our Latest Stock Report on Vitalhub
Vitalhub Trading Down 0.3 %
Shares of VHI traded down C$0.03 during trading hours on Friday, reaching C$8.73. 251,058 shares of the stock traded hands, compared to its average volume of 140,070. Vitalhub has a 52 week low of C$5.38 and a 52 week high of C$12.09. The company has a market cap of C$472.23 million, a price-to-earnings ratio of 141.99, a PEG ratio of 1.18 and a beta of 1.26. The stock has a fifty day simple moving average of C$11.02 and a 200 day simple moving average of C$10.23.
About Vitalhub
(
Get Free Report)
Vitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination and optimization, and patient flow, engagement, and operational visibility solutions.
Further Reading
Before you consider Vitalhub, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vitalhub wasn't on the list.
While Vitalhub currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.